Claims
- 1. A method for preventing or treating various diseases caused by the bacteria belonging to the genus Helicobacter, which comprises administering to a patient in need of treatment a pyridine compound of formula (I') ##STR272## wherein R.sup.1 is a hydrogen, a halogen, an alkyl, an alkoxy, a hydroxyl, an alkoxycarbonyl, a carboxyl, a haloalkyl, a nitro, an amino, a mono- or dialkylamino, an alkoxycarbonylalkylamino or a carboxyalkylamino,
- R.sup.2 and R.sup.3 are the same or different and each is a hydrogen, a halogen or an alkyl,
- --P.dbd.Q-- is --CH.dbd.CH--,
- A is an oxygen atom, a sulfur atom or N(R.sup.4), wherein R.sup.4 is hydrogen, alkyl, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, acyloxyalkyl, alkoxycarbonylalkyl, carboxyalkyl, carbamoyl, carbamoylalkyl, mono- or dialkylcarbamoyl, mono- or dialkylcarbamoylalkyl, thiocarbamoyl, or mono- or dialkylthiocarbamoyl,
- n is 0, 1 or 2,
- B is S(O)p, wherein p is 0, 1 or 2,
- D' is a single bond, an alkylene, an alkylene having substituent or an alkylene having oxo, and
- E' is an alkoxyalkyl, a group of the formula (a), ##STR273## wherein R.sup.6 and R.sup.7 are the same or different and each is hydrogen, alkyl, cycloalkyl, acyl, alkoxycarbonyl, carbamoyl, mono- or dialkylcarbamoyl, optionally substituted phenylcarbamoyl, thiocarbamoyl, mono- or dialkylthiocarbamoyl, optionally substituted phenylthiocarbamoyl, hydroxyalkyl, alkoxycarbonylaklyl, optionally substituted phenylalkylcarbamoyl, optionally substituted phenylalkylthiocarbamoyl, carboxyalkyl, optionally substituted phenyl, optionally substituted phenylalkyl or optionally substituted heteroarylalkyl, or R.sup.6 and R.sup.7 may form, together with the adjoining nitrogen atom, an optionally condensed and optionally substituted heterocyclic ring, or a group of the formula (b) ##STR274## wherein R.sup.8 is hydrogen, alkyl, acyl, carboxyalkyl or optionally substituted phenylalkyl, Y is methylene, oxygen atom or sulfur atom and l and m are the same or different and each is 0 or an integer of 1 to 3;
- or a pharmaceutically acceptable salt thereof as an active ingredient.
- 2. A method for preventing or treating gastrointestinal diseases, which comprises administering to a patient in need of treatment a pyridine compound of formula (I') ##STR275## wherein R.sup.1 is a hydrogen, a halogen, an alkyl, an alkoxy, a hydroxyl, an alkoxycarbonyl, a carboxyl, a haloalkyl, a nitro, an amino, a mono- or dialkylamino, an alkoxycarbonylalkylamino or a carboxyalkylamino,
- R.sup.2 and R.sup.3 are the same or different and each is a hydrogen, a halogen or an alkyl,
- --P.dbd.Q-- is --CH.dbd.CH--,
- A is an oxygen atom, a sulfur atom or N(R.sup.4), wherein R.sup.4 is hydrogen, alkyl, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, acyloxyalkyl, alkoxycarbonylalkyl, carboxyalkyl, carbamoyl, carbamoylalkyl, mono- or dialkylcarbamoyl, mono- or dialkylcarbamoylalkyl, thiocarbamoyl, or mono- or dialkylthiocarbamoyl,
- n is 0, 1 or 2,
- B is S(O)p, wherein p is 0, 1 or 2,
- D' is a single bond, an alkylene, an alkylene having substituent or an alkylene having oxo, and
- E' is an alkoxyalkyl, a group of the formula (a), ##STR276## wherein R.sup.6 and R.sup.7 are the same or different and each is hydrogen, alkyl, cycloalkyl, acyl, alkoxycarbonyl, carbamoyl, mono- or dialkylcarbamoyl, optionally substituted phenylcarbamoyl, thiocarbamoyl, mono- or dialkylthiocarbamoyl, optionally substituted phenylthiocarbamoyl, hydroxyalkyl, alkoxycarbonylalkyl, optionally substituted phenylalkylcarbamoyl, optionally substituted phenylalkylthiocarbamoyl, carboxyalkyl, optionally substituted phenyl, optionally substituted phenylalkyl or optionally substituted heteroarylalkyl, or R.sup.6 and R.sup.7 may form, together with the adjoining nitrogen atom, an optionally condensed and optionally substituted heterocyclic ring, or a group of the formula (b) ##STR277## wherein R.sup.8 is hydrogen, alkyl, acyl, carboxyalkyl or optionally substituted phenylalkyl, Y is methylene, oxygen atom or sulfur atom and 1 and m are the same or different and each is 0 or an integer of 1 to 3;
- or a pharmaceutically acceptable salt thereof as an active ingredient.
- 3. The method of claim 1, wherein the pyridine compound is selected from the group consisting of
- 2-((3-methyl-4-(2-morpholinoethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-(1,2,3,4-tetrahydroisoquinolin-2-yl)ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((4-(2-(N-benzyl-N-methylamino)ethylthio)-3-methyl-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((4-(1-benzyl-4-piperidyl)thio-3-methyl-2-pyridyl)methylthio)-1H-benzimidazole,
- ethyl 2-((3-methyl-4-(2-morpholinoethylthio)-2-pyridyl)methylthio)-1H-benzimidazole-1-carboxylate,
- methyl 2-((3-methyl-4-(2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole-1-carboxylate,
- 4-(2-((2-(1H-benzimidazole-2-yl)thiomethyl-3-methyl-4-pyridyl)-thio)ethyl)morpholine N-oxide,
- 2-((3-methyl-4-(2-acetylaminoethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-benzylaminoethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-(2-hydroxyethylamino)ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-(N,N-di(2-hydroxyethyl)amino)ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-(2-carboxyethylamino)ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-morpholino-2-carboxyethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-dimethylaminoethylthio)-2-pyridyl)methylthio)-1H-benzimidazole and
- 2-((3-methyl-4-(2-(1-acetyl-2-methyl-4-piperazinyl)ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- or a pharmaceutically acceptable salt thereof.
- 4. The method of claim 2, wherein the pyridine compound is selected from the group consisting of
- 2-((3-methyl-4-(2-morpholinoethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-(1,2,3,4-tetrahydroisoquinolin-2-yl)ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((4-(2-(N-benzyl-N-methylamino)ethylthio)-3-methyl-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((4-(1-benzyl-4-piperidyl)thio-3-methyl-2-pyridyl)methylthio)-1H-benzimidazole,
- ethyl 2-((3-methyl-4-(2-morpholinoethylthio)-2-pyridyl)methylthio)-1H-benzimidazole-1-carboxylate,
- ethyl 2-((3-methyl-4-(2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole-1-carboxylate,
- 4-(2-((2-(1H-benzimidazole-2-yl)thiomethyl-3-methyl-4pyridyl)-thio)ethyl)morpholine N-oxide,
- 2-((3-methyl-4-(2-acetylaminoethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-benzylaminoethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-(2-hydroxyethylamino)ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-(N,N-di(2-hydroxyethyl)amino)ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-(2-carboxyethylamino)ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-morpholino-2-carboxyethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- 2-((3-methyl-4-(2-dimethylaminoethylthio)-2-pyridyl)methylthio)-1H-benzimidazole and
- 2-((3-methyl-4-(2-(1-acetyl-2-methyl-4-piperazinyl)ethylthio)-2-pyridyl)methylthio)-1H-benzimidazole,
- or a pharmaceutically acceptable salt thereof.
Priority Claims (2)
Number |
Date |
Country |
Kind |
4-167017 |
Jun 1992 |
JPX |
|
5-272494 |
Oct 1993 |
JPX |
|
Parent Case Info
This is a divisional application of Ser. No. 08/352,183, filed Dec. 1, 1994 now U.S. Pat. No. 5,504,082; which is a continuation-in-part of PCT/JP93/00732, filed May 31, 1993 and PCT/JP94/01800, filed Oct. 26, 1994.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
4746667 |
Carlsson et al. |
May 1988 |
|
5013743 |
Iwahi et al. |
May 1991 |
|
5039806 |
Br andstr am et al. |
Aug 1991 |
|
5045552 |
Souda et al. |
Sep 1991 |
|
5093342 |
Tomoi et al. |
Mar 1992 |
|
5504082 |
Kawakita et al. |
Apr 1996 |
|
Foreign Referenced Citations (5)
Number |
Date |
Country |
0533264A1 |
Mar 1993 |
EPX |
0567643A1 |
Nov 1993 |
EPX |
0585722A1 |
Mar 1994 |
EPX |
WO9212976 |
Aug 1992 |
WOX |
WO9413290 |
Jun 1994 |
WOX |
Non-Patent Literature Citations (6)
Entry |
Suerbraum et al., Eur. J. Clin. Microbiol. Infect. Dis., 10(2), 92-93 (1991). |
Derwent Publications, Ltd., Abstract No. B0186 (1994) (abstract of JP 06100449-A). |
Derwent Publications, Ltd., Abstract No. B0200 (1991) (abstract of JO 3038523A). |
Derwent Publications, Ltd., Abstract No. B0205 (1991) (abstract of JO 3048680A). |
Derwent Publications, Ltd., Abstract No. B0143 (1991) (abstract of JO 3052887A). |
Derwent Publications, Ltd., Abstract No. B0125 (1991) (abstract of JO 3052812A). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
352183 |
Dec 1994 |
|